Drug Trial Radar · NCT02108288
Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Apr 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Apr 2014
Primary completion
May 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- First posted
- Apr 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Who can join
- Male only, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating the combination drug will be determined.
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
OPC-1085EL ophthalmic solutionDrug
Carteolol long-acting ophthalmic solutionDrug
Latanoprost ophthalmic solutionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of CarteololTime frame: Day 1 and Day 7
- Cmax of Latanoprost AcidTime frame: Day 1 and Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Kansai Region, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.